(Hypertension. 2001;37:753.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
From the Department of Physiology (A.N., D.S.A.M., M.W., L.G.N.), Tulane University Health Sciences Center, New Orleans, La; and Research Equipment Center (A.M.), Kagawa Medical University, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan.
Correspondence to Akira Nishiyama, MD, PhD, Department of Physiology, SL-39, Tulane University Health Sciences Center, 1430 Tulane Ave, New Orleans, LA 70112-2699. E-mail anishiy{at}tulane.edu
| Abstract |
|---|
|
|
|---|
Key Words: adenosine tubuloglomerular feedback kidneys acetazolamide furosemide
| Introduction |
|---|
|
|
|---|
TGF-mediated afferent arteriolar vasoconstriction occurs in response to increases in distal nephron NaCl or solute concentration at the level of the macula densa cells.1 3 9 The nature of the signaling mechanisms that elicit the TGF-mediated changes in afferent arteriolar tone has remained unresolved; however, the possible participation of extracellular ATP as an important mediator of this mechanism has received increased support.3 10 11 12 13 14 15 16 17 18 Although the macula densa cells have abundant mitochondria, they have reduced levels of Na+,K+-ATPase,12 making the macula densa cells good candidates for a source of extracellular ATP. Micropuncture and microperfusion experiments13 have demonstrated that stop-flow pressure feedback responses to increases in late proximal perfusion rate are markedly blunted during peritubular capillary infusion with saturating doses of ATP, suggesting that ATP modulates the macula densadependent TGF mechanism. Chan et al14 performed immunohistochemistry studies and found that the preglomerular renal vasculature expresses abundant P2X receptors, whereas efferent arterioles appear to be devoid of such receptors. Studies with the blood-perfused juxtamedullary nephron preparation showed that P2-purinoceptor desensitization, receptor saturation, or blockade markedly attenuates autoregulatory adjustments in afferent arteriolar diameter after acute changes in renal perfusion pressure.15 Majid et al16 demonstrated that the ability of the renal vasculature to exhibit autoregulation-mediated changes in renal vascular resistance (RVR) in response to alterations in renal arterial pressure (RAP) is markedly attenuated during P2-purinoceptor saturation by intra-arterial infusions with high doses of ATP. Recently, Bell et al17 demonstrated that the macula densa cells have a maxi-Cl- channel that is permeable to ATP and also demonstrated that increases in macula densa NaCl concentrations result in the release of ATP from macula densa cells.
We recently demonstrated a direct relationship between autoregulation-related changes in RVR and changes in renal interstitial ATP levels during stepwise reductions in RAP within the autoregulatory range.11 These results support the hypothesis that autoregulation-dependent changes in RVR are mediated by corresponding changes in interstitial ATP concentrations. The aim of the present study was to examine further the relationship between renal interstitial ATP and RVR in response to changes in RAP under conditions of enhanced or attenuated TGF activity. Specially, we hypothesized that during pressure changes, autoregulation-mediated adjustments in RVR and interstitial ATP levels are closely associated to TGF activity. To test this hypothesis, renal interstitial ATP concentrations were measured using an in vivo microdialysis method11 19 20 at different RAP within the autoregulatory range under conditions of enhanced activity of the TGF mechanism elicited pharmacologically with the carbonic anhydrase inhibitor acetazolamide, which inhibits net proximal tubular reabsorption rate and thus increases NaCl and solute delivery to the macula densa cells.21 22 23 Further studies were also performed during inhibition of the TGF response by furosemide.4 5 7 8 9 Because adenosine has also been suggested as a potential mediator of the TGF mechanism24 25 26 27 28 and ATP can be metabolized to adenosine,3 10 18 29 we also evaluated the changes in renal interstitial concentrations of adenosine.
| Methods |
|---|
|
|
|---|
Animal Preparation
Experiments were carried out on mongrel dogs weighing
from 17 to 23 kg. The animals were anesthetized with
pentobarbital sodium (30 mg/kg IV) and administered additional doses as
required. The surgical preparation of the animals and basic
experimental techniques are identical to those previously
described.11 16 30
Experimental Protocol
At least 90 minutes before the start of the
experimental protocol, the left common carotid artery was partially
constricted to elevate the basal level of RAP to
130 mm Hg.
This allowed examination of the pressure-flow relationship over a wider
range of arterial
pressure.11 16 30
The experimental protocol was started with renal
interstitial fluid and urine collections for 2 consecutive
10-minute periods at spontaneous RAP (n=12). With an adjustable renal
arterial clamp, RAP was reduced within the renal
autoregulatory range to
100 mm Hg (step 1) and
75
mm Hg (step 2). At each level of RAP, 5 minutes were allowed for
stabilization before a 10-minute sampling period. At 60 minutes after
release of the renal arterial clamp, renal
interstitial fluid and urine collections were performed at
spontaneous RAP for 2 consecutive 10-minute periods. Next,
acetazolamide (Sigma Chemical Co) was infused
intra-arterially at a rate of 100
µg · kg-1 · min-1
in 6 dogs. After a 5-minute initiation of acetazolamide
infusion, 3 consecutive 5-minute dialysate and urine samples were
collected. Subsequently, RAP was reduced to
100 mm Hg (step 1)
and
75 mm Hg (step 2) during acetazolamide
infusion. At each level of RAP, 5 minutes was allowed for stabilization
before two 5-minute dialysate and urine sampling periods were made. In
the other 6 dogs, furosemide (Sigma Chemical Co), instead of
acetazolamide, was infused intra-arterially at
a rate of 10
µg · kg-1 · min-1.
The experimental protocols and sample collections in this study were
identical to those described earlier. To minimize
acetazolamide- and furosemide-induced body fluid loss,
urine losses were replaced quantitatively with warm (37°C)
isotonic saline that contained 6 mmol/L KCl and was infused
intravenously, with the rate adjusted every 2
minutes.
Analytical Procedures
ATP and adenosine concentrations were
determined with the luciferin-luciferase assay and HPLC-fluorometric
analysis, respectively, as previously
reported.11 20
Inulin, sodium, and potassium concentrations in urine and plasma were
measured as previously
reported.11 16 30
Statistical Analysis
The values are presented as mean±SEM.
Statistical comparisons of the differences were performed with 1- or
2-way ANOVA for repeated measures combined with Newman-Keuls post hoc
test. Correlation of the responses was made with Spearmans test.
P<0.05 was considered
statistically significant.
| Results |
|---|
|
|
|---|
|
Figure 1A illustrates the changes in RVR in response to reductions in RAP before and during acetazolamide infusion (n=6). Control RVR averaged 28.4±1.9 mm Hg · mL-1 · min-1 · g-1 and decreased significantly by -20±3% in step 1 and -41±2% in step 2 (P<0.05, respectively) before acetazolamide infusion. Acetazolamide infusion for 20 minutes significantly increased RVR from 28.0±2.1 to 33.1±2.5 mm Hg · mL-1 · min-1 · g-1 (P<0.05). During acetazolamide infusion, RVR decreased significantly in response to reductions in RAP (by -19±3% to 26.4±1.6 mm Hg · mL-1 · min-1 · g-1 in step 1 and by -40±2% to 19.9±1.2 mm Hg · mL-1 · min-1 · g-1 in step 2, P<0.05, respectively; Figure 1A). The pressure-induced reductions in RVR in the presence of acetazolamide infusion were not significantly different from the changes in RVR observed before acetazolamide infusion (by -20±3% in step 1 and by -41±2% in step 2, respectively). As reported previously,11 reductions in RAP significantly decreased renal interstitial concentrations of ATP from 9.0±1.0 to 6.2±0.8 nmol/L in step 1 and to 4.2±0.8 nmol/L in step 2 (P<0.05, respectively) under control conditions (Figure 1B). Within this pressure range, the percent changes in ATP concentrations were highly correlated with the percent changes in RAP (r=0.77, P<0.05) and RVR (r=0.80, P<0.01) (Figure 1C). Acetazolamide significantly increased renal interstitial concentrations of ATP from 8.4±0.7 to 15.5±1.4 nmol/L. During acetazolamide infusion, ATP levels were significantly decreased during stepwise reductions in RAP by -36±4% to 9.5±0.8 nmol/L in step 1 and by -54±2% to 7.2±0.7 nmol/L in step 2 (P<0.05, respectively). The pressure-induced reductions in renal interstitial ATP concentrations during acetazolamide infusion were similar to those observed before acetazolamide administration (by -31±2% in step 1 and by -55±4% in step 2). Furthermore, the percent changes in ATP concentrations were highly correlated with the percent changes in RVR during acetazolamide infusion (r=0.71, P<0.01). As shown in Figure 1C, the slopes of the regression equations for both conditions were very similar (0.69 versus 0.66). Control average dialysate adenosine concentration was 114±14 nmol/L, which was not altered significantly in response to changes in RAP (113±14 nmol/L in step 1 and 109±14 nmol/L in step 2). In addition, the percent changes in adenosine concentrations did not exhibit any correlation with the percent changes in RAP (r=0.19, P=0.54) or RVR (r=0.03, P=0.76). Acetazolamide did not alter renal interstitial concentrations of adenosine (from 99±10 to 100±12 nmol/L). Furthermore, adenosine levels were not altered in response to reductions in RAP during acetazolamide infusion (93±12 nmol/L in step 1 and 94±12 nmol/L in step 2).
|
Changes in Renal Interstitial
Concentrations of ATP and Adenosine in Response to Reductions
in RAP During Diminished Activity of the TGF Mechanism
Table 2 summarizes the changes in renal
hemodynamics, urine flow, and sodium excretion during
stepwise reductions in RAP before and during furosemide infusion (n=6).
Before furosemide infusion, RBF and GFR did not change significantly in
response to reductions in RAP within this pressure range, and urine
flow, urinary excretion of sodium, and fractional excretion of sodium
were significantly decreased during reductions in RAP, as described
previously. Furosemide (10
µg · kg-1 · min-1)
did not cause any significant change in MAP and RAP but significantly
increased RBF and GFR (P<0.05,
respectively). During furosemide infusion, there was marked impairment
of autoregulatory efficiency. RBF and GFR significantly decreased in
response to reductions in RAP (by -14±3% and -11±3% in step 1
and by -26±2% and -18±4% in step 2,
P<0.05, respectively). Urine
flow, urinary excretion of sodium, and fractional excretion of sodium
were significantly increased by furosemide infusion
(P<0.05, respectively). During
furosemide infusion, urine flow, urinary excretion of sodium, and
fractional excretion of sodium did not change in step 1, but these
values were significantly decreased in step 2
(P<0.05,
respectively).
|
Furosemide significantly decreased RVR from 30.9±1.6 to 23.1±1.6 mm Hg · mL-1 · min-1 · g-1 (P<0.05; Figure 2A). During furosemide infusion, pressure-induced reductions in RVR were not observed in step 1 (21.4±1.2 mm Hg · mL-1 · min-1 · g-1). In step 2, RVR was significantly decreased by -18±2% to 21.1±1.1 mm Hg · mL-1 · min-1 · g-1 during furosemide infusion; however, the autoregulation-mediated reductions in RVR during furosemide infusion were significantly smaller than those observed before furosemide infusion (by -41±2%, P<0.05, Figure 2A). Figure 2B illustrates the changes in renal interstitial concentrations of ATP in response to reductions in RAP before and during furosemide infusion (n=6). Before furosemide infusion, reductions in RAP significantly decreased renal interstitial concentration of ATP (from 9.1±1.3 to 6.5±0.9 nmol/L in step 1 and to 4.1±0.6 nmol/L in step 2, P<0.05, respectively). Furosemide infusion for 20 minutes significantly decreased renal interstitial concentrations of ATP from 8.9±1.4 to 5.0±0.8 nmol/L. These levels were not altered in response to reductions in RAP during furosemide infusion (4.7±0.7 nmol/L in step 1 and 4.7±0.8 nmol/L in step 2). In addition, there was no correlation between the percent changes in ATP concentrations and the percent changes in RVR during furosemide administration (r=0.22, P=0.30, Figure 2C). Furosemide did not alter renal interstitial adenosine concentrations (from 92±12 to 95±10 nmol/L). Furthermore, adenosine levels were not altered in response to changes in RAP during furosemide infusion (97±10 nmol/L in step 1 and 93±11 nmol/L in step 2).
|
In a separate experimental series, acetazolamide (100 µg · kg-1 · min-1) or furosemide (10 µg · kg-1 · min-1) was infused for 50 minutes to examine the possibility of any time-dependent changes in renal hemodynamics and function as well as interstitial ATP and adenosine levels (n=5, respectively). Acetazolamide significantly increased ATP levels from 6.8±0.7 to 13.3±1.6 nmol/L (15- to 20-minute sampling period, P<0.05), and these concentrations remained elevated for the duration of sampling up to 50 minutes (14.3±1.9 nmol/L). Acetazolamide infusion for 20 minutes significantly decreased RBF and GFR from 3.80±0.12 and 0.91±0.06 mL · min-1 · g-1 to 3.26±0.15 and 0.77±0.22 mL · min-1 · g-1 (P<0.05), respectively, which were not different from the values measured 50 minutes after the onset of the infusion period (3.26±0.15 and 0.78±0.03 mL · min-1 · g-1). Furosemide significantly decreased ATP levels from 7.9±0.9 to 4.6±0.7 nmol/L (15- to 20-minute sampling period, P<0.05), and these concentrations remained reduced for the duration of sampling up to 50 minutes (4.7±1.0 nmol/L). RBF and GFR were significantly increased by 20-minute furosemide infusion from 3.98±0.29 and 0.82±0.04 mL · min-1 · g-1 to 5.31±0.44 and 0.95±0.05 mL · min-1 · g-1 (P<0.05), respectively, and remained at the same levels for 50 minutes (5.32±0.55 and 0.97±0.09 mL · min-1 · g-1, respectively). Acetazolamide- or furosemide-induced changes in urine flow, urinary excretion of sodium and potassium, and fractional excretion of sodium also remained stable during the observation period. Furthermore, acetazolamide or furosemide infusion for 50 minutes did not significantly alter MAP, RAP, plasma concentrations of sodium and potassium, and renal interstitial concentrations of adenosine.
| Discussion |
|---|
|
|
|---|
We observed that during acetazolamide infusion, RBF and GFR were decreased but autoregulated at the lower plateau in response to reductions in RAP; thus, the autoregulatory adjustments in RVR were fully preserved. These results are consistent with recent studies by Ichihara and Navar21 demonstrating that the TGF-mediated autoregulatory efficiency of afferent arteriolar diameter responses to alterations in renal perfusion pressure is maintained in acetazolamide-treated kidneys. As previously reported,11 acetazolamide increased renal interstitial concentrations of ATP at control arterial pressures. During acetazolamide infusion, the RAP-induced changes in renal interstitial concentrations of ATP were maintained, although at a different level, and were positively correlated with the changes in RVR. In addition, the slopes of the correlations between changes in ATP levels and RVR were similar before and during acetazolamide treatment. These results indicate that increased activity of the TGF mechanism does not alter the pattern of the relationship between the autoregulation-induced adjustments in RVR and the renal interstitial ATP concentrations. In contrast, inhibition of the TGF response with furosemide resulted in significant decreases in renal interstitial concentrations of ATP. Furthermore, furosemide elicited a marked impairment of RBF and GFR autoregulatory efficiency as well as the autoregulation-associated alterations in RVR, as previously reported by other investigators.6 7 The key finding is that pressure-induced changes in renal interstitial ATP levels were not observed in furosemide-treated kidneys. In addition, the association between the autoregulatory adjustments in RVR and renal interstitial ATP concentrations was not observed during furosemide infusion. Thus, these results support a prediction of the hypothesis that during changes in RAP, autoregulation-mediated adjustments in RVR due to changes in activity of the TGF mechanism are elicited by the corresponding changes in interstitial ATP concentrations.
Although the present results demonstrate that renal interstitial concentrations of ATP change in response to alterations in TGF activity, the exact sources of renal interstitial fluid ATP have remained uncertain. It has been shown that renal epithelial cells,32 vascular smooth muscle cells,33 34 and endothelial cells34 release ATP into the surrounding pericellular fluid. Furthermore, flow-induced shear stress on vessel walls can stimulate ATP release from mesenteric35 and aortic36 endothelial cells. The present experiment demonstrates that interstitial fluid ATP levels are highly responsive to alterations in the activity of the TGF mechanism caused by changes in RAP as well as by treatment with acetazolamide or furosemide. In addition, preliminary reports by Bell et al17 indicate that ATP is released from macula densa cells into the pericellular fluid. These observations suggest the possibility that at least part of the released extracellular ATP comes from macula densa cells. It should be recognized, however, that changes in interstitial concentrations of ATP are the result of release, removal, and metabolism and are not solely reflected by the changes in ATP release. The activity of ATPases on cell membranes has been reported to be quite high, and extracellular ATP could be constantly being degraded,3 10 18 29 thus indicating that the interstitial ATP concentrations represent residual levels of those present at their direct effector sites.11
Several micropuncture studies24 25 26 27 28 demonstrating that local administration of high doses of adenosine receptor antagonists reduce the magnitude of TGF-mediated reductions in stop-flow pressure and single nephron filtration rate in response to increases in distal nephron perfusion rate have suggested a role for adenosine in the transmission of the TGF signals. However, this hypothesis has remained controversial because systemic administration of adenosine antagonists does not block RBF and GFR autoregulation37 or TGF responses.26 Previously, we observed that renal interstitial adenosine levels were not altered in response to reductions in RAP within the autoregulatory range.11 19 In the present study, we observed that adenosine levels were not altered significantly during augmented TGF activity by acetazolamide or inhibition of the TGF response by furosemide. Thus, these data provide no support to the hypothesis that renal interstitial adenosine serves as a mediator of either the autoregulatory mechanism or the TGF response. It should also be noted that, although ATP can be metabolized to ADP, AMP and adenosine,3 10 18 29 complete and immediate hydrolysis of all available ATP would still not yield sufficiently high levels of these substances to cause comparable vasoconstriction, as described previously.3 10 11
In conclusion, the present study demonstrates a positive correlation between the autoregulation-induced adjustments in RVR and renal interstitial ATP concentrations during control conditions and when intensity of the TGF-dependent signals is augmented. Furthermore, blockade of TGF-dependent actions on RVR resulted in loss of this relationship. These data are consistent with the hypothesis that autoregulation-dependent adjustments in RVR that are elicited by alterations in activity of the TGF mechanism are mediated by the corresponding changes in interstitial ATP concentrations.
| Acknowledgments |
|---|
Received November 24, 2000; first decision November 28, 2000; accepted December 14, 2000.
| References |
|---|
|
|
|---|
2. Walker M III, Harrison-Bernard LM, Cook AK, Navar LG. Dynamic interaction between myogenic and TGF mechanisms in afferent arteriolar blood flow autoregulation. Am J Physiol. 2000;279:F858F865.
3.
Navar LG, Inscho
EW, Majid DSA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine
regulation of the renal microcirculation.
Physiol Rev. 1996;76:425536.
4.
Takenaka T,
Harrison-Bernard LM, Inscho EW, Carmines PK, Navar LG. Autoregulation
of afferent arteriolar blood flow in juxtamedullary nephrons.
Am J Physiol. 1994;267:F879F887.
5. Moore LC, Casellas D. Tubuloglomerular feedback dependence of autoregulation in rat juxtamedullary afferent arterioles. Kidney Int. 1990;37:14021408.[Medline] [Order article via Infotrieve]
6.
Just A, Wittmann U,
Ehmke H, Kirchheim HR. Autoregulation of renal blood flow in the
conscious dog and the contribution of the
tubuloglomerular feedback.
J Physiol (Lond). 1998;506:275290.
7. Duchin KL, Peterson LN, Burke TJ. Effect of furosemide on renal autoregulation. Kidney Int. 1977;12:379386.[Medline] [Order article via Infotrieve]
8.
Sanchez-Ferrer CF,
Roman RJ, Harder DR. Pressure-dependent contraction of rat
juxtamedullary afferent arterioles. Circ
Res. 1989;64:790798.
9. Schnermann J, Briggs J. Concentration-dependent sodium chloride transport as the signal in feedback control of glomerular filtration rate. Kidney Int. 1982;12:S82S89.
10. Inscho EW, Mitchell KD, Navar LG. Extracellular ATP in the regulation of renal microvascular function. FASEB J. 1994;8:319328.[Abstract]
11.
Nishiyama A,
Majid DSA, Taher KA, Miyatake A, Navar LG. Relation between renal
interstitial ATP concentrations and autoregulation-mediated
changes in renal vascular resistance. Circ
Res. 2000;86:656662.
12. Schnermann J, Marver D, ATPase activity in macula densa cells of the rabbit kidney. Pflugers Arch. 1986;407:8286.[Medline] [Order article via Infotrieve]
13.
Mitchell KD,
Navar LG. Modulation of tubuloglomerular feedback
responsiveness by extracellular ATP.
Am J Physiol. 1993;264:F458F466.
14.
Chan CM, Unwin
RJ, Bardini M, Oglesby IB, Ford AP, Townsend-Nicholson A, Burnstock G.
Localization of P2X1 purinoceptors by autoradiography
and immunohistochemistry in rat kidneys.
Am J Physiol. 1998;274:F799F804.
15.
Inscho EW, Cook
AK, Navar LG. Pressure-mediated vasoconstriction of juxtamedullary
afferent arterioles involves P2-purinoceptor activation.
Am J Physiol. 1996;271:F1077F1085.
16.
Majid DSA, Inscho
EW, Navar LG. P2 purinoceptor saturation by adenosine
triphosphate impairs renal autoregulation in dogs.
J Am Soc Nephrol. 1999;10:492498.
17. Bell PD, Lapointe J-Y, Sabirov R, Hayashi S, Okada Y. Maxi-chloride channel in macula densa cells: possible pathway for ATP release. FASEB J. 2000;14:A134. Abstract.
18. Chan CM, Unwin RJ, Burnstock G. Potential functional roles of extracellular ATP in kidney and urinary tract. Exp Nephrol. 1998;6:200207.[Medline] [Order article via Infotrieve]
19. Nishiyama A, Miura K, Miyatake A, Fujisawa Y, Yue W, Fukui T, Kimura S, Abe Y. Renal interstitial concentration of adenosine during endotoxin shock. Eur J Pharmacol. 1999;385:209216.[Medline] [Order article via Infotrieve]
20.
Nishiyama A,
Miyatake A, Aki Y, Fukui T, Rahman M, Kimura S, Abe Y.
Adenosine A1 receptor
antagonist KW-3902 prevents hypoxia-induced renal
vasoconstriction. J Pharmacol Exp
Ther. 1999;291:988993.
21. Ichihara A, Navar LG. Neuronal NOS contributes to biphasic autoregulatory response during enhanced TGF activity. Am J Physiol. 1999;277:F113F120.
22.
Ichihara A,
Inscho EW, Imig JD, Navar LG. Neuronal nitric oxide synthase modulates
rat renal microvascular function. Am
J Physiol. 1998;274:F516F524.
23. Persson AE, Wright FS. Evidence for feedback mediated reduction of glomerular filtration rate during infusion of acetazolamide. Acta Physiol Scand. 1982;114:17.[Medline] [Order article via Infotrieve]
24.
Wilcox CS, Welch
WJ, Schreiner GF, Belardinelli L. Natriuretic and
diuretic actions of a highly selective adenosine A1
receptor antagonist. J Am
Soc Nephrol. 1999;10:714720.
25.
Schnermann J,
Weihprecht H, Briggs JP. Inhibition of
tubuloglomerular feedback during adenosine1
receptor blockade. Am J
Physiol. 1990;258:F553F561.
26.
Franco M, Bell
PD, Navar LG. Effect of adenosine A1 analogue on
tubuloglomerular feedback mechanism.
Am J Physiol. 1989;257:F231F236.
27.
Schnermann J.
Effect of adenosine analogues on
tubuloglomerular feedback responses.
Am J Physiol. 1988;255:F33F42.
28. Thomson S, Bao D, Deng A, Vallon V. Adenosine formed by 5'-nucleotidase mediates tubuloglomerular feedback. J Clin Invest. 2000;106:289298.[Medline] [Order article via Infotrieve]
29.
Gordon EL,
Pearson JD, Dickinson ES, Moreau D, Slakey LL. The hydrolysis of
extracellular adenine nucleotides by arterial
smooth muscle cells: regulation of adenosine production
at the cell surface. J Biol
Chem. 1989;264:1898618992.
30.
Majid DSA, Omoro
SA, Chin SY, Navar LG. Intrarenal nitric oxide activity and pressure
natriuresis in anesthetized dogs.
Hypertension. 1998;32:266272.
31. Walker M III, Nishiyama A, Majid DSA, Taher KA, Navar LG. Dynamic autoregulatory interactions between tubuloglomerular feedback and myogenic mechanisms controlling blood flow in canine kidneys. FASEB J. 2000;14:A134. Abstract.
32.
Taylor AL, Kudlow
BA, Marrs KL, Gruenert DC, Guggino WB, Schwiebert EM. Bioluminescence
detection of ATP release mechanisms in epithelia.
Am J Physiol. 1998;275:C1391C1406.
33. Katsuragi T, Tamesue S, Sato C, Sato Y, Furukawa T. ATP release by angiotensin II from segments and cultured smooth muscle cells of guinea-pig taenia coli. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:796799.[Medline] [Order article via Infotrieve]
34. Pearson J, Gordon J. Vascular endothelial and smooth muscle cells in culture selectivity release adenine nucleotides. Nature. 1979;281:384386.[Medline] [Order article via Infotrieve]
35. Ralevic V, Milner P, Kirkpatrick KA, Burnstock G. Flow-induced release of adenosine 5'-triphosphate from endothelial cells of the rat mesenteric arterial bed. Experientia. 1991;48:3134.
36. Milner P, Bodin P, Loesch A, Burnstock G. Rapid release of endothelin and ATP from isolated aortic endothelial cells exposed to increased flow. Biochem Biophys Res Commun. 1990;170:649656.[Medline] [Order article via Infotrieve]
37. Ibarrola AM, Inscho EW, Vari RC, Navar LG. Influence of adenosine receptor blockade on renal function and renal autoregulation. J Am Soc Nephrol. 1991;2:991999.[Abstract]
This article has been cited by other articles:
![]() |
G. B. Silva and J. L. Garvin Extracellular ATP inhibits transport in medullary thick ascending limbs: role of P2X receptors Am J Physiol Renal Physiol, November 1, 2009; 297(5): F1168 - F1173. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. B. Silva and J. L. Garvin Akt1 mediates purinergic-dependent NOS3 activation in thick ascending limbs Am J Physiol Renal Physiol, September 1, 2009; 297(3): F646 - F652. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. W. Inscho Mysteries of Renal Autoregulation Hypertension, February 1, 2009; 53(2): 299 - 306. [Full Text] [PDF] |
||||
![]() |
G. B. Silva and J. L. Garvin TRPV4 mediates hypotonicity-induced ATP release by the thick ascending limb Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1090 - F1095. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Graciano, A. Nishiyama, K. Jackson, D. M. Seth, R. M. Ortiz, M. C. Prieto-Carrasquero, H. Kobori, and L. G. Navar Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension Am J Physiol Renal Physiol, January 1, 2008; 294(1): F161 - F169. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Oppermann, P. B. Hansen, H. Castrop, and J. Schnermann Vasodilatation of afferent arterioles and paradoxical increase of renal vascular resistance by furosemide in mice Am J Physiol Renal Physiol, July 1, 2007; 293(1): F279 - F287. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Rivera, S. Zhang, B. S. Fuller, B. Edwards, T. Seki, M.-H. Wang, M. B. Marrero, and E. W. Inscho P2 receptor regulation of [Ca2+]i in cultured mouse mesangial cells Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1380 - F1389. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pedersen, Z. Vajda, H. Stodkilde-Jorgensen, S. Nielsen, and J. Frokiaer Furosemide increases water content in renal tissue Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1645 - F1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Mullins, M. A. Bailey, and J. J. Mullins Hypertension, Kidney, and Transgenics: A Fresh Perspective Physiol Rev, April 1, 2006; 86(2): 709 - 746. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Silva, W. H. Beierwaltes, and J. L. Garvin Extracellular ATP Stimulates NO Production in Rat Thick Ascending Limb Hypertension, March 1, 2006; 47(3): 563 - 567. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nishiyama, K. E. Jackson, D. S. A. Majid, M. Rahman, and L. G. Navar Renal interstitial fluid ATP responses to arterial pressure and tubuloglomerular feedback activation during calcium channel blockade Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H772 - H777. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Vekaria, D. G. Shirley, J. Sevigny, and R. J. Unwin Immunolocalization of ectonucleotidases along the rat nephron Am J Physiol Renal Physiol, February 1, 2006; 290(2): F550 - F560. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Komlosi, A. Fintha, and P. D. Bell Renal Cell-to-Cell Communication via Extracellular ATP Physiology, April 1, 2005; 20(2): 86 - 90. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Unwin, M. A. Bailey, and G. Burnstock Purinergic Signaling Along the Renal Tubule: The Current State of Play Physiology, December 1, 2003; 18(6): 237 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Just and W. J. Arendshorst Dynamics and contribution of mechanisms mediating renal blood flow autoregulation Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R619 - R631. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yao, M. Suwa, B. Li, K. Kawamura, T. Morioka, and T. Oite ATP-Dependent Mechanism for Coordination of Intercellular Ca2+ Signaling and Renin Secretion in Rat Juxtaglomerular Cells Circ. Res., August 22, 2003; 93(4): 338 - 345. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Sprague, J. J. Olearczyk, D. M. Spence, A. H. Stephenson, R. W. Sprung, and A. J. Lonigro Extracellular ATP signaling in the rabbit lung: erythrocytes as determinants of vascular resistance Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H693 - H700. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nishiyama and L. G. Navar ATP mediates tubuloglomerular feedback Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2002; 283(1): R273 - R275. [Full Text] [PDF] |
||||
![]() |
A. Nishiyama and L. G. Navar Response to J. Schnermann: Adenosine mediates tubuloglomerular feedback Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2002; 283(1): Ra278 - Ra280. [Full Text] [PDF] |
||||
![]() |
A. Nishiyama, D. M. Seth, and L. G. Navar Renal Interstitial Fluid Concentrations of Angiotensins I and II in Anesthetized Rats Hypertension, January 1, 2002; 39(1): 129 - 134. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |